o NoneEntity Type
0001674416
Inception Genomics AG
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 CRISPR Therapeutics AG
Jurisdiction of Incorporation/OrganizationSWITZERLAND 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 CRISPR Therapeutics AG 
Street Address 1Street Address 2
 Baarerstrasse 14 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 Zug SWAZILAND 6300 +41 (0)41 561 32 77 



3. Related Persons
Last NameFirst NameMiddle Name
NovakRodger
Street Address 1Street Address 2
C/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
KulkarniSamarth
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HoTony
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
BehbahaniAli
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
BolzonBradley
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
TomsicekMichael
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
KasingerJames
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
GeorgeSimeon
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
HighKatherine
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
GreeneJohn
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
KleinLawrence
Street Address 1Street Address 2
c/o CRISPR Therapeutics AGBaarerstrasse 14
CityState/Province/CountryZIP/Postal Code
ZugSWITZERLAND6300
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  x Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-03-11 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities o Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $ 1000000 USD o Indefinite
Total Amount Sold $ 1000000 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
  


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more CRISPR Therapeutics Charts.
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more CRISPR Therapeutics Charts.

Crispr Therapeutics Ag News

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Tuesday 23 April 2024 (2 weeks ago) • GlobeNewswire Inc.
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
Wednesday 3 April 2024 (1 month ago) • GlobeNewswire Inc.
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Monday 1 April 2024 (1 month ago) • GlobeNewswire Inc.
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
Wednesday 13 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 22 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 22 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Wednesday 21 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Wednesday 21 February 2024 (2 months ago) • Edgar (US Regulatory)
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Wednesday 21 February 2024 (2 months ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 144 - Report of proposed sale of securities
Friday 16 February 2024 (3 months ago) • Edgar (US Regulatory)
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
Friday 16 February 2024 (3 months ago) • GlobeNewswire Inc.

More Crispr Therapeutics Ag News Articles